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Obesity is a global pandemic affecting both children and adults. According to Institute for Health Metrics and Evaluation database, 2.1 billion people, or 29% of the world's population, were either overweight or obese in 2013. Obesity is a risk factor for cardiovascular diseases, stroke, type 2 diabetes, high blood pressure and certain types of cancer ([@B50]), which imposes profound economic and health care burdens on the individual and society. Genetic factors are estimated to account for 67% of variance in body weight and human adiposity ([@B32]). More than 150 genetic loci have been associated with the development of obesity, yet these loci only explain 2% of overall obesity cases ([@B13]), highlighting an urgent need to expand our knowledge of the molecular mechanisms leading to obesity.

Obesity arises due to unbalanced energy intake and expenditure, both of which are critically controlled by a complex system that is comprised of different organs including the liver, pancreas, muscle, adipose tissues, gastrointestinal tract and brain. Within the system, the brain serves as a pivotal hub for information integration and processing, as different signals generated by the peripheral tissues, including leptin produced in the adipose tissues ([@B80]), insulin produced by the pancreas ([@B68]; [@B7]), ghrelin produced by the stomach ([@B39]), glucagon-like peptide 1 (GLP-1) and peptide YY 3-36 (PYY~3-36~) produced by the intestine ([@B59]; [@B9]). These peripheral signals converge into specific brain regions such as the hypothalamus and brainstem ([@B53]; [@B69]; [@B38]; [@B52]), which function to change neuronal activities in these regions to regulate energy intake and expenditure.

Neuronal activities are not merely controlled by secreted factors from peripheral tissues. Neurotrophic factors, which are secreted proteins synthesized locally in the brain, signal through their respective transmembrane receptors and act upon various neuronal populations. Neurotrophic factors are functionally versatile, which facilitate neuronal growth, differentiation, survival, synaptic formation and plasticity during development, as well as in the mature brain ([@B35]; [@B25]; [@B62]). To date, two types of neurotrophic factors, including brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF), have been linked to the central control of energy homeostasis, as mutations in the genes encoding BDNF and its receptor tropomyosin receptor kinase B (TrkB) are found in patients with severe obesity ([@B75]; [@B16]; [@B19]), and administration of CNTF protein leads to body weight loss in both human and mice ([@B36]; [@B15]). Considering their important and diverse roles in the brain, it is likely that additional neurotrophic factors are involved in the regulation of energy homeostasis, so that this process can be manipulated in a highly precise and regulated manner.

Indeed, emerging studies suggest that mesencephalic astrocyte-derived neurotrophic factor (MANF), a recently identified neurotrophic factor, could also serve as a regulator of food intake and body weight. Given that both the protein structure and functional mechanisms of MANF are different from most other neurotrophic factors, whether MANF is truly a neurotrophic factor remains a matter of debate. In this review, we refer MANF as a non-canonical neurotrophic factor. We begin with an overview of MANF as a neuroprotective molecule; we then present the recent evidence supporting the role of MANF in mediating energy homeostasis and compare MANF with BDNF and CNTF, the two neurotrophic factors that have been extensively studied; we also discuss the latest research about the endogenous functions of MANF in the brain, and argue that besides promoting neuronal survival, MANF could possess additional roles in mediating neuronal development and activities.

Manf: a New Addition to the Neurotrophic Factor Family
======================================================

Mesencephalic astrocyte-derived neurotrophic factor was initially discovered in the conditioned medium from ventral mesencephalic cell line 1 (VMCL1), in 2003 ([@B49]). Being considered as a non-canonical neurotrophic factor, MANF exhibits several major distinctions comparing to other previously known neurotrophic factors: (1) most canonical neurotrophic factors evolved early in vertebrate history, whereas MANF represents a much more ancient protein species, as MANF homologs are found in invertebrates, such as fruit fly *Drosophila melanogaster* ([@B46]), nematode *Caenorhabditis elegans* ([@B5]) and sponge *Suberites domuncula* ([@B54]); (2) MANF does not share any protein sequence homology with canonical neurotrophic factors. In fact, the N-terminus of MANF is homologous to saposin-like proteins ([@B47]), and the C-terminus resembles SAF-A/B, Acinus and PIAS (SAP) proteins ([@B23]), suggesting two distinct functions ([@B29]); (3) like canonical neurotrophic factors, MANF is able to work extracellularly to regulate cellular signaling cascades ([@B71]; [@B77],[@B78]; [@B57]), potentially through an unidentified transmembrane receptor. But more intriguingly, MANF is also localized intracellularly in the endoplasmic reticulum (ER), and functions as an ER stress response protein ([@B37]; [@B4]). In fact, through interacting with glucose-regulated protein 78 (GRP78), an ER chaperone, most of intracellular MANF is retained in the lumen of ER ([@B41]). Upon ER stress, the interaction is attenuated, and MANF is released to the extracellular space ([@B14]). The dual functional locations make MANF a unique target for research, which may shed light on novel therapeutic strategies that are previously inaccessible to canonical neurotrophic factors.

Early functional studies about MANF are focused on its role in Parkinson's disease (PD), as genetic knockdown or knockout of *manf* in zebrafish or fruit fly lead to defective development of the dopamine system ([@B46]; [@B11]), and administration of purified MANF protein or viral vectors expressing MANF has beneficial effects in both cellular and animal models of PD ([@B49]; [@B81]; [@B64]; [@B20]). Endogenous MANF protein is abundantly expressed in the rodent brain, as well as non-neuronal tissues, such as liver, salivary gland and testis ([@B30]). Emerging evidence indicates that MANF is protective in a broad range of disease conditions, including cerebral ischemia ([@B2]; [@B76]; [@B34]), myocardial infarction ([@B14]), Spinocerebellar ataxia type 17 ([@B71]; [@B17]), and retinal degeneration ([@B40]; [@B31]). Although the exact mechanism remains elusive, both extracellular and intracellular MANF forms are believed to contribute to the protective effects. Several lines of evidence support the extracellular functions of MANF: in cultured cells, addition of recombinant MANF protein into the culture medium is able to activate pro-survival signaling pathways, including PKC, AKT/GSK3β, AMPK/mTOR and STAT3 pathways ([@B71]; [@B77],[@B78]; [@B57]); in fruit fly and mouse, administration of recombinant MANF protein ameliorated retinal degeneration caused by various damaging stimuli, and the protective capacity could be derived from immune modulation (induction of alternative activation of microglia) ([@B40]); in rodent models of PD and stroke, administration of recombinant MANF protein reduced neuronal death ([@B2]; [@B64]; [@B72]). A major obstacle to advance our knowledge about extracellular MANF is that the identity of its plasma membrane receptor remains unknown, although different mechanisms have been proposed to account for the cellular uptake of MANF ([@B24]; [@B5]). There are also several studies supporting the intracellular functions of MANF: MANF is enriched in the ER and is induced by unfolded protein response (UPR) ([@B37]; [@B4]); upon UPR and ER stress, MANF could be either secreted to the extracellular space ([@B41]; [@B21]), or enter the nucleus to suppress the transcriptional activities of NF-κB pathway ([@B10]).

Manf as a Regulator of Energy Homeostasis
=========================================

Energy homeostasis is achieved by balanced energy intake and expenditure. As the first neurotrophic factor known to be involved in the control of energy homeostasis, BDNF is believed to play a crucial role in both processes. Two-day food restriction was able to selectively reduce *Bdnf* mRNA level in the ventromedial nucleus of hypothalamus (VMH) in mice ([@B70]), an area known to regulate energy intake. Intracerebroventricular infusion of recombinant human BDNF decreased food intake in rats ([@B26]), whereas genetic deletion of *Bdnf* gene in the VMH or the paraventricular nucleus of hypothalamus (PVH), another brain area related to energy intake, led to hyperphagia and obesity in mice ([@B60]; [@B3]). Nonetheless, it remains to be determined where the BDNF expressing neurons project to, and how BDNF functions to suppress food intake. On the other hand, injection of BDNF protein into either the VMH or PVH increased energy expenditure in rats, via escalating heat production and resting metabolic rate ([@B65], [@B66]). These results are further corroborated by the finding that deletion of *Bdnf* gene in the PVH reduced energy expenditure in mice, via decreasing locomotor activity and thermogenesis ([@B3]). Again, the neural circuits that mediate the effect of BDNF on energy expenditure remain to be elucidated, although it has been found that the BDNF expressing neurons in the medial and posterior PVH could project to the spinal cord and promote adaptive thermogenesis through polysynaptic connections to brown adipose tissues ([@B3]). Taken together, BDNF functions to counteract obesity through reducing energy intake and enhancing energy expenditure.

Ciliary neurotrophic factor belongs to the interleukin 6 (IL-6) cytokine family ([@B22]). Originally discovered as a pro-survival factor for chick ciliary ganglion neurons ([@B1]), CNTF mRNA and protein are not only expressed in neuronal tissues, but also widely distributed in non-neuronal tissues, including heart, lung, liver, kidney and testis ([@B42], [@B43]). Similar to MANF, CNTF is localized intracellularly, and is secreted to the extracellular space during cell injury ([@B27]; [@B55]; [@B51]). CNTF is essential for the survival of motor neurons ([@B33]), hence has been tested as a therapy for amyotrophic lateral sclerosis (ALS). However, quite unexpectedly, CNTF treatment in ALS patients led to marked body weight loss ([@B36]). This phenomenon has been reproduced in mice, as systemic administration of CNTF reduced hyperphagia and obesity in mice deficient with functional leptin (ob/ob mice) or leptin receptor (db/db mouse) ([@B15]). The mechanism underlying the effect of CNTF is believed to be partially from the leptin signaling, as both leptin and CNTF activate the Janus tyrosine kinase--signal transducers and activators of transcription (JAK--STAT) signaling ([@B61]; [@B48]), especially the STAT3 transcription factor, which is a key molecule involved in energy balance ([@B8]). Nonetheless, null mutations of *Cntf* were not associated with either hyperphagia or obesity in mice or human ([@B56]; [@B12]), indicating that the endogenous function of CNTF might not be related to energy homeostasis.

Compared with the neurotrophic factors described above, evidence supporting the involvement of MANF in energy homeostasis is only beginning to emerge (Figure [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}). MANF is abundantly expressed in the brain ([@B30]). In rats, the expression of MANF is particularly high during early development (between postnatal day 3 and 5) in the brain, but gradually declines as the brain matures. Nonetheless, high expression of MANF sustains into adulthood in selected brain regions, including hypothalamus, the brain region that crucially regulates energy homeostasis ([@B67]). Interestingly, an exome sequencing study identified *MANF* as a potential causative gene for a 22-year-old woman patient with type 2 diabetes mellitus, hypothyroidism, primary hypogonadism, short stature, mild intellectual disability, obesity, deafness, high myopia, microcephaly and partial alopecia ([@B74]). More clinical data are needed to firmly establish the link between MANF and obesity development in human.

![The functions of neurotrophic factors in the hypothalamus. **(A)** BDNF expressing neurons are found in the PVN, DMH, and VMH of the hypothalamus. BDNF functions in these regions to reduce food intake and increase energy expenditure, in a non-cell-autonomous manner. **(B)** The receptor for CNTF is found in the PVN and ARC of the hypothalamus. Administration of CNTF alters neuronal activities in the ARC, but not in the PVN. The outcome of CNTF administration is reducing food intake and increasing energy expenditure. **(C)** MANF is expressed in the PVN, DMH, VMH, and ARC of the hypothalamus. Increasing MANF expression in the hypothalamus, or specifically in the ARC leads to increased food intake, in a cell-autonomous manner, as administration of recombinant MANF protein does not change food intake. The function of MANF in other regions of the hypothalamus remains to be established. Arrows with solid lines, experimental evidence is currently available; arrows with dotted lines, experimental evidence is currently lacking. PVN, paraventricular hypothalamus; DMH, dorsomedial hypothalamus; VMH, ventromedial hypothalamus; ARC, arcuate nucleus.](fphys-09-01725-g001){#F1}
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Comparison of BDNF, CNTF, and MANF in energy homeostasis.

  Name   Protein structure                                                                                                                                                             Expression pattern                                                      Overall function in energy homeostasis                   Important studies/findings
  ------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  BDNF   N-terminal signal peptide; followed by a common, basic consensus sequence of the furin type; C-terminal conserved sequence of nerve growth factor (NGF) domain.               High expression in the brain, low expression in non-neuronal tissues.   Reduce food intake, increase energy expenditure.         BDNF is enriched in the ventromedial hypothalamus (VMH); brain administration of BDNF reduces food intake ([@B70]). Deletion of BDNF in the VMH and dorsomedial hypothalamus (DMH) leads to hyperphagia ([@B60]).
                                                                                                                                                                                                                                                                                                                        Deletion of BDNF in the paraventricular hypothalamus (PVH) leads to hyperphagia and reduced energy expenditure ([@B3]).
                                                                                                                                                                                                                                                                                                                        
  CNTF   Lacks a signal peptide; resembles alpha-helical cytokine family which is characterized by a bundle of four anti-parallel helices.                                             High expression in the brain, heart, lung, liver, kidney and testis.    Reduce food intake, increase energy expenditure.         Brain administration of CNTF reduces food intake and adiposity ([@B15]). Germline deletion of CNTF does not lead to hyperphagia or obesity ([@B33]).
                                                                                                                                                                                                                                                                                                                        
  MANF   N-terminal signal peptide; followed by a domain homologous to saposin-like proteins (SAPLIPs); C-terminus homologous to SAF-A/B, Acinus and PIAS (SAP) protein superfamily.   High expression in the brain, liver, salivary gland and testis.         Increase food intake, no effect on energy expenditure.   MANF is enriched in the ARC, VMH and PVH; deletion of MANF in the hypothalamus leads to reduced food intake; overexpression of MANF in the hypothalamus leads to hyperphagia ([@B71]).
                                                                                                                                                                                                                                                                                                                        

The most direct support for the role of MANF in controlling energy homeostasis comes from a recent study on mice ([@B73]): MANF was found to be enriched in different nuclei in mouse hypothalamus, including the arcuate nucleus (ARC), VMH and PVH; two-day food restriction significantly increased MANF expression in the hypothalamus; increasing or decreasing MANF expression selectively in the hypothalamus led to hyperphagia or hypophagia, respectively. MANF appeared to specifically regulate energy intake, while leaving energy expenditure unaffected. In terms of mechanistic studies, MANF was shown to function in the ER to mediate insulin response, a signaling pathway known to regulate energy homeostasis in the brain ([@B63]), via influencing the activity of a kinase named PIP4k2b. Taken together, these results demonstrate that the activity of MANF leads to enhanced energy intake and functions opposite to BDNF and CNTF. Nonetheless, there remain several open questions that are critical for elucidating the exact role of MANF in the hypothalamus: what is the specific function of MANF in each hypothalamic region or neuronal type; are there any other intracellular or extracellular mechanisms that account for the hyperphagic effect of MANF? It has been well established that obesity could cause ER stress ([@B45]), and hypothalamic ER stress leads to leptin/insulin resistance and hyperphagia ([@B79]; [@B44]). Given that MANF protects against ER stress, it appears counterintuitive that increased MANF expression in the hypothalamus is associated with hyperphagia. Nonetheless, in most cases, the up-regulation of MANF during ER stress was caused by acute treatment, such as ER stress inducing chemicals, or ischemic and epileptic insults ([@B4]; [@B30]). It remains unknown whether MANF is up-regulated under chronic ER stress conditions, such as during the development of obesity.

It is worth noting that MANF seems to be closely linked to the insulin signaling, as germline knockout of *Manf* in mice led to a progressive reduction of pancreatic β cells, the type of cell responsible for the synthesis and storage of insulin ([@B28]). On the other hand, addition of recombinant MANF protein was able to protect human pancreatic β cells against stress-induced cell death ([@B18]). Homozygous *Manf* knockout mice showed retarded body growth, which is in agreement with the obesity phenotype found in a transgenic mouse model overexpressing MANF ([@B73]). Intriguingly, brain specific knockout of *Manf* during early development, which is mediated by Cre recombinase driven by *Nestin* promoter, did not result in any obvious phenotypes ([@B28]). It is possible that certain compensatory mechanisms exist during development. Indeed, a similar phenomenon was found in BDNF studies: deletion of *Bdnf* in the adult PVH caused much more robust hyperphagia and obesity than deletion of Bdnf in the PVH during embryonic development using Cre recombinase driven by *Sim1* promoter ([@B6]; [@B3]).

Conclusion and Future Perspectives
==================================

As discussed above, researchers have begun to reveal the potential roles of MANF in mediating energy homeostasis. The functional mechanisms of MANF remain largely unclear. Especially, the dual modes of action both inside and outside of the cell add an additional layer of complexity, which at the same time, offer an exciting research opportunity. It is highly desirable to identify the plasma membrane receptor for MANF, so that we could get a clear picture about the signaling pathways controlled by MANF. It is equally important to clarify the intracellular molecular mechanisms of MANF, not only in the ER, but potentially in other cellular organelles or structures. In addition, identification of the neuronal types and the related neural circuits that MANF acts upon would provide much needed information not only to expand our understanding of the central control of energy homeostasis, but also to design therapeutic approaches to combat the development of obesity. MANF is widely distributed throughout the brain ([@B30]; [@B73]), and it affords protection to neurons in different brain regions, such as the cortex, cerebellum and substantia nigra ([@B64]; [@B71]; [@B57]). Notably, the expression of MANF appears to be higher in the developing brain ([@B67]). These results suggest that MANF could possess important cell type-dependent functions in brain regions other than the hypothalamus, especially during early development. Indeed, a recent study indicates that MANF could promote neurite extension and neuronal migration in the developing cortex ([@B58]). Continual efforts are needed for us to build a comprehensive image about the neurobiology of MANF in the brain.
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